'Ozempic slows aging' is the kind of headline that moves markets and medicine cabinets. The study behind the latest round of them is real, and considerably more modest than the framing suggests. In a randomized, placebo-controlled trial of 108 adults with HIV-related fat changes, weekly semaglutide - the drug in Ozempic and Wegovy - slowed one measure of biological aging by about 9 percent compared with placebo [1][2].
The measure is an 'epigenetic clock' called DunedinPACE, which estimates how fast a body is aging; the trial also found semaglutide lowered a second clock linked to mortality risk [2]. That is a genuine signal, and the researchers are the first to say what it is not. 'We are not saying that semaglutide reverses aging or makes people younger,' the lead author, Michael Corley of UC San Diego, said - describing instead 'a signal that it may slow some of the biological processes associated with aging' [1].
Several things keep this short of a longevity breakthrough. No regulator has approved semaglutide to slow aging, and the researchers call the work exploratory, with much larger trials needed [1]. The people studied were a specific group - adults with HIV-associated fat redistribution - not the general population, so the finding does not simply transfer to a healthy person hoping to age more slowly [1]. A 9 percent relative slowing of one clock is a lead worth chasing, not a proven therapy [2].
The record, then, is a hopeful and narrow one: a widely used drug nudged a marker of biological aging in a small, specific trial, and the scientists who ran it are asking for caution, not a victory lap [1]. The distance between that and 'Ozempic reverses aging' is the distance between a promising early result and the thing the headlines turned it into [2].
